Minerva Neurosciences, Inc. announced that the company has received a refusal to file letter from the U.S. Food and Drug Administration (FDA) regarding the company's New Drug Application (NDA) for roluperidone for the treatment of negative symptoms in patients with schizophrenia. The FDA has indicated that the company can request a Type A meeting to discuss the content of the refusal to file letter.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.48 USD | -1.59% | +1.64% | -59.67% |
May. 01 | Minerva Neurosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Feb. 27 | Sector Update: Health Care Stocks Ease Late Afternoon | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-59.67% | 17.34M | |
+9.58% | 115B | |
+12.41% | 107B | |
-3.64% | 21.6B | |
-12.38% | 22.31B | |
-6.68% | 19.19B | |
-3.35% | 18.23B | |
-38.57% | 17.62B | |
+7.51% | 14.26B | |
+35.67% | 12.37B |
- Stock Market
- Equities
- NERV Stock
- News Minerva Neurosciences, Inc.
- Minerva Neurosciences, Inc. Receives Refusal to File Letter from FDA for its New Drug Application for Roluperidone for the Treatment of Negative Symptoms in Schizophrenia